AMG-757-20240178 A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)



Mary Beth Wilwerding, RN Admin@NEcancertrials.com



Available at Nebraska Cancer Specialists

Interested in More Information?

Please fill out the form below. Someone will get back to you as soon as possible.

"*" indicates required fields

Name*

Email*

Phone*

Message*